Pancreatic Cancer

Armed malaria protein found to kill cancer cells

A new type of cancer therapy based on seemingly unrelated elements of malaria and cancer is showing promise for development. Kairos Therapeutics, a Vancouver-based biotech company spun-out of The Centre for Drug Research ...

5 hours ago
popularity5 comments 0

New drug targets the source of cancer renewal

A new class of drug that reduces cancer recurrence and spread may soon be available, with South Australian biopharmaceutical company Bionomics having passed review by the US Food and Drug Administration (FDA) with their product ...

Sep 25, 2015
popularity122 comments 0

Professor fights cancer with hedgehogs

A Binghamton University biochemist has discovered a new way to fight cancer, one that attacks only the cancer cells and promises fewer side effects. He hunts hedgehogs.

Oct 06, 2015
popularity4 comments 0

Rare cancer responds unusually well to new treatment

Vienna, Austria: Patients with advanced gastrointestinal neuroendocrine tumours (NETs) have limited treatment options and there are few oncologists who are specialised in this relatively rare disease. But now results from ...

Sep 27, 2015
popularity28 comments 0

Pancreatic cancer refers to a malignant neoplasm originating from transformed cells arising in tissues forming the pancreas. The most common type of pancreatic cancer, accounting for 95% of these tumors, is adenocarcinoma (tumors exhibiting glandular architecture on light microscopy) arising within the exocrine component of the pancreas. A minority arise from islet cells, and are classified as neuroendocrine tumors. The symptoms that lead to diagnosis depend on the location, the size, and the tissue type of the tumor. They may include abdominal pain and jaundice (if the tumor compresses the bile duct).

Pancreatic cancer is the fourth most common cause of cancer death across the globe. Pancreatic cancer often has a poor prognosis: for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, respectively; for local disease the 5-year survival is approximately 20% while the median survival for locally advanced and for metastatic disease, which collectively represent over 80% of individuals, is about 10 and 6 months respectively.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Closer view of the brain

For Harvard neurobiologist Jeff Lichtman, the question hasn't been whether scientists will ever understand the brain, but how closely they'll have to look before they do.